Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,938 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Takakuwa T, et al. Among authors: matsuda m. Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31. Eur J Haematol. 2021. PMID: 33476404
Successful allogeneic hematopoietic stem cell transplantation in a young patient with Richter syndrome presenting with chronic lymphocytic leukemia and diffuse large B-cell lymphoma with different cell origins.
Rai S, Matsuda M, Yamairi N, Eguchi G, Iwanaga T, Morita Y, Tanaka H, Tatsumi Y, Ashida T, Matsumura I. Rai S, et al. Among authors: matsuda m. Intern Med. 2013;52(2):273-6. doi: 10.2169/internalmedicine.52.8731. Epub 2013 Jan 15. Intern Med. 2013. PMID: 23318862 Free article.
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y; KMF investigators. Kobayashi T, et al. Among authors: matsuda m. Int J Hematol. 2015 Jan;101(1):37-45. doi: 10.1007/s12185-014-1696-6. Epub 2014 Nov 11. Int J Hematol. 2015. PMID: 25385278
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators. Matsumura-Kimoto Y, et al. Among authors: matsuda m. Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29. Int J Hematol. 2018. PMID: 29380179
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Morita Y, et al. Among authors: matsuda m. Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26. Cancer Sci. 2018. PMID: 30007103 Free PMC article. Clinical Trial.
3,938 results